Sulbactam/ETX 2514

Drug Profile

Sulbactam/ETX 2514

Alternative Names: beta-lactam/ETX-2514; ETX 2514/Sulbactam; ETX-2514SUL

Latest Information Update: 19 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Entasis Therapeutics
  • Class Anti-infectives; Antibacterials; Penicillins
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acinetobacter infections

Most Recent Events

  • 07 Oct 2017 Adverse events data from a phase I trial in Acinetobacter infections (In volunteers) presented at the IDWeek 2017 (IDW-2017)
  • 03 Oct 2017 Entasis Therapeutics initiates enrolment in a phase I trial for Acinetobacter infections (In volunteers, In renal impairment and end-stage renal disease patients) in USA (NCT03310463)
  • 28 Sep 2017 Sulbactam/ETX 2514 receives Fast Track designation for Acinetobacter infections [IV,Injection] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top